RLS-0071: Dual Target Inhibition in Support of Hypoxic Ischemic Encephalopathy

Time: 11:30 am
day: Track B - Day 1 AM


  • RLS-0071 is a novel, dual-targeting peptide with upstream control of inflammatory pathways. Mutually supportive inhibition of complement and cellular inflammatory processes support lead candidate RLS- 0071 development in hypoxic ischemic encephalopathy
  • Discussing the Phase 2 clinical trial in progress assessing safety, pharmacokinetics and pharmacodynamic biomarkers planned in HIE
  • Demonstrating a clean safety profile in Phase 1 human trial with encouraging target engagement data